1. In Vivo

A Management Shake-Up At Pfizer Raises Questions

2011 is likely to be a defining year for Pfizer and the Big Pharma has hit the ground running. In early December, the board of directors announced a management shake-up, as CEO Jeff Kindler resigned unexpectedly and the board simultaneously elected veteran Pfizer executive Ian Read to replace him. In the ensuing weeks, the board also named a new non-executive chairman, George Lorch, former chairman and CEO of the diversified conglomerate Armstrong Holdings. In addition, it consolidated leadership of several business units and appointed some of those leaders to its executive committee.

2011 is likely to be a defining year for Pfizer Inc. and the Big Pharma has hit the ground running. In early December, the board of directors announced a management shake-up, as 55-year-old CEO Jeff Kindler resigned unexpectedly and the board simultaneously elected veteran Pfizer executive Ian Read to replace him. The announcement had the marking of a coup d'état, given the abruptness and the critical juncture of the drugmaker's fortunes. ( See "Pfizer Turns To Insider Ian Read To See It Into Post-Lipitor Era," "The Pink Sheet" DAILY, December 6, 2010Also see "Pfizer Turns To Insider Ian Read To See It Into Post-Lipitor Era" - Pink Sheet, 6 December, 2010..)

In the ensuing weeks, the board also named a new non-executive chairman, George Lorch, former chairman and CEO of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business Strategy

More from In Vivo

BioBytes: AI-Related Deals In Q2 ‘25

 
• By David Wild

When it came to AI-related deals, the second quarter of 2025 was characterized by mostly modest financings.

Titans Of Pharma: Lilly’s Ricks Tops Big Pharma Pay Chart

 
• By Eleanor Malone, Edwin Elmhirst, and Kosh Naran

The big pharma CEO with the highest-valued compensation in 2024 was David Ricks of Eli Lilly, while Pfizer and J&J executives slipped into third and fourth place behind AbbVie's now retired chief Richard Gonzalez. European firms brought up the rear.

Thinking Outside The BIOX: Bioxodes Takes Novel Approach To Intracerebral Hemorrhage

 
• By Jo Shorthouse

Although intracerebral hemorrhage accounts for only 13% of all strokes, it is responsible for approximately 40% of stroke-related deaths. A Belgian biotech is looking in unusual places to rectify this situation, namely in a tick’s mouth.